Company intelligence / Profile preview

Hangzhou Wutong Tree Pharmaceutical

Hangzhou, Zhejiang, Chinaen.wutshu.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The lead asset, ILB-2109, an A2aR antagonist for advanced malignant solid neoplasms, has reached Phase 2. Other assets are in earlier stages. Four clinical approvals have been obtained since founding; one project was successfully transferred for RMB48.5 million (~$7M USD). No published pivotal data yet.

Therapeutic areas: OncologyPulmonology
Modalities: Small molecule drug
Industry: Biotech

Drug pipeline

2 assets

WTS-005

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

WuXi AppTec

Beyond the preview

Go deeper on Hangzhou Wutong Tree Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Wutong Tree Pharmaceutical.

Explore the full profile